PLXProtalix BioTherapeutics, Inc.同业对比
Protalix BioTherapeutics, Inc. 与Biological Products, (No Diagnostic Substances)的逐项对比:市值、估值、增长、盈利能力、质量与总回报,以及在同业组内的排名。所有数值均由引擎从 SEC 申报与延迟行情计算,排名仅为组内排序位置 —— 描述性数据,非投资建议。
完整同业对比
同业组:同 SIC 行业分类 (Biological Products, (No Diagnostic Substances))| 公司 | 市值 | 市盈率(TTM) | 市净率 | 市销率 | 营收同比增长 | 净利同比增长 | 息税前利润率 | 净资产收益率 | 投入资本回报率 | 皮氏 F 值 | 一年总回报 | 股息率 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PLX本股 | $209M#8 | 11.3x#2 | 2.9x#9 | 4.0x#3 | -1.2%#5 | -325.2%#15 | -10.4%#1 | -9.2%#1 | -12.3%#1 | 3#1 | 9.3%#5 | — |
| LCTX | $258M#1 | — | 4.2x#12 | 17.7x#7 | 53.2%#3 | -241.4%#14 | -251.6%#6 | -104.3%#12 | — | — | -47.8%#10 | — |
| OCGN | $258M#2 | — | — | 58.4x#10 | 8.8%#4 | -25.9%#7 | -1425.7%#8 | — | — | — | -50.2%#11 | — |
| LXEO | $257M#3 | — | 1.1x#4 | 393.3x#11 | — | -1.7%#4 | -16706.0%#11 | -42.5%#8 | — | — | -65.3%#15 | — |
| FATE | $245M#4 | — | 1.6x#7 | 36.9x#8 | -51.2%#7 | 26.8%#2 | -2222.4%#10 | -88.8%#11 | -102.3%#2 | — | 62.9%#1 | — |
| CABA | $242M#5 | — | 1.2x#5 | — | — | -44.9%#11 | — | -79.7%#9 | — | — | -52.3%#12 | — |
| ALEC | $230M#6 | — | — | 10.9x#5 | -79.1%#8 | -20.2%#6 | -741.3%#7 | — | — | — | 42.1%#3 | — |
| PALI | $216M#7 | 1.9x#1 | 1.8x#8 | — | — | -16.2%#5 | — | -13.8%#2 | — | — | -37.8%#9 | — |
| IKT | $208M#9 | — | 1.4x#6 | — | -100.0%#9 | -75.4%#12 | — | -31.5%#5 | — | — | -8.0%#7 | — |
| ARTV | $206M#10 | — | 0.6x#1 | — | -100.0%#9 | -28.3%#8 | — | -24.1%#3 | — | — | 12.0%#4 | — |
| DTIL | $194M#11 | 21.7x#3 | 3.7x#11 | 5.7x#4 | -50.1%#6 | -738.0%#16 | -152.2%#3 | -88.3%#10 | — | — | -6.1%#6 | — |
| ACOG | $180M#12 | — | 3.4x#10 | 17.6x#6 | — | -39.8%#10 | -221.7%#5 | -39.0%#7 | — | — | 44.0%#2 | — |
| IVVD | $172M#13 | — | 1.0x#3 | 3.2x#2 | 110.5%#1 | 69.1%#1 | -104.0%#2 | -29.0%#4 | — | — | -63.5%#14 | — |
| LIMN | $169M#14 | — | 563.0x#13 | — | — | -187.8%#13 | — | -3395.2%#13 | -170.3%#3 | — | -96.2%#16 | — |
| STRO | $157M#15 | — | — | 1.5x#1 | 65.2%#2 | 15.9%#3 | -154.5%#4 | — | — | — | -12.9%#8 | — |
| TARA | $144M#16 | — | 0.9x#2 | 48.7x#9 | — | -28.7%#9 | -2189.6%#9 | -35.6%#6 | — | — | -52.4%#13 | — |
数值来自 SEC 申报与延迟行情;排名仅为该组内的排序位置 —— 描述性数据,不构成评级或建议。 数据构建于 2026-11-04。
数据来自 SEC XBRL 申报与延迟行情 · 排名为组内排序 · 仅供参考 · 非投资建议